source
- FDA unveils Global Reliance Disclosure Program to speed international drug approvalsThe FDA announced the Global Reliance Disclosure Program (GRDP) on November 17, 2026, describing it as a new effort to share its drug and biologic approval packages with other health authorities.…
- FDA rejects ivonescimab for lung cancer; J&J to acquire Ollin Biosciences for up to $3.3B, Senate votes on FDA commissionerThe FDA has denied the application for ivonescimab as a treatment for lung cancer, halting its development for that indication. Johnson & Johnson announced a deal to purchase Ollin Biosciences, a…